Drugs / Sotevtamab
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07488884 | Jun 2026 → Jun 2027 expected | pancreatic ductal adenocarcinoma | ImmunityBio, Inc. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT02412462 | Apr 2015 → Jan 2017 | metastatic malignant neoplasm | Alethia Biotherapeutics | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06225843 | Feb 2024 → Mar 2026 overdue | colorectal cancer | Alethia Biotherapeutics | Recruiting | No outcome recorded |
| Phase 2 | NCT04364620 | Feb 2021 → Dec 2023 | non-small cell lung carcinoma | Alethia Biotherapeutics | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sotevtamab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07488884 ↗ |
| Known as | AB-16B5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04364620 ↗ |
| Action | Inhibit | “inhibits the activity of the secreted form of clusterin (sCLU)” NCT02412462 ↗ |
| Modality | Monoclonal antibody | “AB-16B5 is a humanized monoclonal antibody” NCT02412462 ↗ |
| Route | Intravenous | “60-minute intravenous weekly infusion” NCT02412462 ↗ |